CJC-1295 for Muscle Gain: Protocol, Dosing, and What to Expect

What this protocol is for

CJC-1295 is the GH-releasing hormone half of the canonical growth-hormone stack. The mechanism is straightforward: CJC binds the GHRH receptor in the pituitary and amplifies the pulse that releases endogenous growth hormone. Paired with a GHRP like Ipamorelin (which acts on a different receptor), the two compounds layer onto each other's signaling to produce a meaningfully larger GH release than either alone. Increased GH drives IGF-1, which drives the nitrogen-retention and lean-tissue gains the protocol is built for.

The clinical pattern is consistent. Lifters past peak puberty whose natural GH curve has flattened. Returning sportsmen whose body composition is not responding to training and diet alone the way it used to. Men running a hard hypertrophy block who want every recovery advantage the body offers. Anecdotally, users report meaningful body composition shifts over 8 to 12 weeks: 1 to 2 kg of lean mass on top of an already-good programme, better recovery between hard sessions, improved sleep quality as a downstream effect of the GH pulse pattern.

Used by many in the recovery / biohacking space alongside the work that always mattered for hypertrophy: progressive overload, protein, sleep, recovery. The peptide does not replace any of these. It amplifies the cellular environment they work in. Run this as a tactical, legal performance layer on top of a well-built training block, not as a substitute for one. The molecule has two forms (with DAC and without DAC) and the choice between them changes the dosing rhythm significantly. Get the form right.

Dose for muscle gain

CJC-1295 with DAC: 1 to 2 mg subcutaneous once weekly. Drug-affinity complex extends the half-life to roughly 5 to 8 days; weekly single dose is the standard rhythm. CJC-1295 without DAC (Mod GRF 1-29): 100 to 300 mcg subcutaneous 1 to 3 times daily. Without DAC mimics the natural GH pulse pattern more closely; with DAC is more convenient and produces steady-state elevation. Both forms are typically stacked with a GHRP (Ipamorelin most commonly) to amplify GH release.

Cycle length

8 to 12 weeks for muscle-gain protocols. The longer cycle matters because IGF-1 elevation takes 3 to 4 weeks to reach steady-state and the lean-tissue gains land in weeks 6 to 12. Continuous use beyond 16 weeks does not have strong supporting evidence; pituitary feedback regulation kicks in and the protocol effective signal degrades. Cycle off 4 to 6 weeks between runs.

Stack pairings

Commonly stacked with Ipamorelin.

Expected timeline

Week 1–3: improved sleep quality, deeper recovery between training sessions. Subjective signal precedes the body composition signal. Week 4–6: IGF-1 elevation reaches steady-state; appetite typically increases. Week 6–12: lean tissue gains land. Most users report 1 to 2 kg of lean mass over a full cycle on top of a well-built training block.

Common mistakes

• Mixing up CJC-1295 with DAC and without DAC. The dosing rhythms are completely different. Without DAC requires multiple daily injections; with DAC is weekly. Running the wrong dose-frequency wastes molecule.
• Running CJC-1295 alone without a GHRP. The single-receptor signal under-delivers; the stack with Ipamorelin (which acts on the ghrelin receptor) produces a meaningfully larger GH pulse. Most protocols use both.
• Stopping at 6 weeks because no muscle has shown up yet. CJC for hypertrophy is back-loaded; the visible body composition gains land in weeks 8 to 12.
• Treating the protocol as a substitute for the training block. The peptide amplifies the cellular environment; the training and protein intake are what drive the actual hypertrophy direction.
• Ignoring the appetite increase. Weight gain on this protocol can be lean or fat depending on diet management. Track protein intake; control discretionary calories.